Dr. Brammer on Brentuximab Vedotin for Patients With T-Cell Lymphoma

Jonathan E. Brammer, MD
Published: Thursday, Oct 26, 2017



Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses brentuximab vedotin (Adcetris) for patients with T-cell lymphoma.

An issue in the landscape that is currently being explored is whether brentuximab vedotin is effective in the frontline setting as has been shown in Hodgkin lymphoma. Preliminary studies have shown that brentuximab vedotin does seem to have some efficacy in other CD30-positive T-cell lymphomas.
SELECTED
LANGUAGE


Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses brentuximab vedotin (Adcetris) for patients with T-cell lymphoma.

An issue in the landscape that is currently being explored is whether brentuximab vedotin is effective in the frontline setting as has been shown in Hodgkin lymphoma. Preliminary studies have shown that brentuximab vedotin does seem to have some efficacy in other CD30-positive T-cell lymphomas.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x